medwireNews@

Alexander Schauwvlieghe discusses their retrospective cohort study evaluating two approaches for antibiotic therapy in patients with acute myeloid leukaemia or myelodysplastic syndromes who develop febrile neutropenia during induction chemotherapy (2:45).

Amer Zeidan reports on their analysis of ASTRAL-1 trial data indicating that both azacitidine and decitabine are valid options for geriatric patients with treatment-naïve acute myeloid leukaemia (6:25).

Amer Zeidan discusses phase 1b trial findings demonstrating promising efficacy and manageable tolerability of venetoclax plus azacitidine in patients with relapsed or refractory myelodysplastic syndrome (5:55).

Andrew Wei presents updated findings from the phase 3 VIALE-C acute myeloid leukaemia trial, discussing how these and the VIALE-A data cement the role of venetoclax as a first-line option for older patients and those ineligible for intensive chemotherapy (7:41).

Benjamin Teh presents trial data showing high seroprotection rates against all strains with a two-dose schedule of seasonal influenza vaccination, irrespective of vaccine type, in individuals who have undergone autologous haematopoietic stem cell transplantation (5:56).

Charles Herbaux presents the primary analysis of the phase 2 GATA study showing the potential of combining atezolizumab, obinutuzumab and venetoclax for the treatment of relapsed or refractory diffuse large B-cell lymphoma (5:11).

Christina Peters outlines why the FORUM trial results support the continued use of total body irradiation in paediatric and adolescent patients undergoing haematopoietic stem cell transplantation for acute lymphoblastic leukaemia (7:52).

Courtney DiNardo discusses the phase 3 VIALE-A study supporting the addition of venetoclax to azacitidine as a new standard of care option for the first-line treatment of acute myeloid leukaemia patients who are ineligible for intensive chemotherapy (4:31).

Elizabeth Phillips describes their phase 2 trial showing that the combination of inotuzumab ozogamicin and R-CVP is efficacious for certain subgroups of treatment-naïve, R-CHOP-ineligible patients with diffuse large B-cell lymphoma, and outlines the next steps to improve treatment outcomes (5:59).

Matthew Wilson outlines the key results of their study evaluating the optimal timing for administering high-dose methotrexate to reduce the risk of central nervous system relapse in patients with diffuse large B-cell lymphoma (6:13).

Nilanjan Ghosh shares phase 1b trial findings showing high response rates with lisocabtagene maraleucel, a CD19-directed chimeric antigen receptor T-cell agent, as second-line therapy in patients with aggressive, relapsed or refractory, large B-cell non-Hodgkin lymphomas who were ineligible for haematopoietic stem cell transplantation (6:46).

Philippe Moreau tells us why the phase 3 IKEMA trial supports the addition of the anti-CD38 agent isatuximab to carfilzomib plus dexamethasone as a potential new standard of care for relapsed or refractory multiple myeloma (5:52).

W Fraser Symmans takes us through their patient-level pooled analysis identifying residual cancer burden as a predictive factor for recurrence across all breast cancer subtypes, and its subsequent potential to inform treatment choice (6:49).

Joaquín Gavilá highlights the phase 2 SOLTI-1402/CORALLEEN trial findings demonstrating comparable clinical benefit and reduced toxicity of combined neoadjuvant endocrine and CDK 4/6 inhibitor therapy versus chemotherapy in patients with high-risk luminal B breast cancer (2:44).

Icro Meattini shares long-term findings from their phase 3 trial pitting accelerated partial breast against whole breast irradiation in women with early-stage breast cancer (1:39).

Gerardo Umanzor discusses phase 3 findings showing improved survival and reduced neuropathy with orally administered versus intravenous paclitaxel in patients with metastatic breast cancer (3:12).

Rowan Chlebowski outlines the findings from the Women's Health Initiative trials investigating the effect of oestrogen, either alone or with progestin, on breast cancer risk, and puts them in context of recent opposing data (4:10).

Milan Radovich shares data suggesting a role for circulating tumour DNA in identifying triple-negative breast cancer patients likely to experience relapse after surgery (2:26).

Luca Gianni outlines initial results from the NeoTRIPaPDL1 study of neoadjuvant atezolizumab plus chemotherapy in triple-negative breast cancer, and speculates on the reasons behind the differences with the KEYNOTE-522 findings (3:57).

Peter Schmid presents subgroup analyses from the KEYNOTE-522 trial of neoadjuvant and adjuvant pembrolizumab in patients with early-stage triple-negative breast cancer (4:54).

Rashmi Murthy reports on the HER2CLIMB study pointing to a role for the selective HER2–tyrosine kinase inhibitor tucatinib in the metastatic breast cancer setting (3:12).

Sara Tolaney takes us through the ATEMPT adjuvant therapy trial comparing trastuzumab emtansine with trastuzumab plus paclitaxel in patients with stage I HER2-positive breast cancer (4:01).

Daniel Persky gives the results of the large National Clinical Trials Network S1001 study, confirming the benefits of four cycles of R-CHOP for PET-negative patients with limited stage diffuse large B-cell lymphoma (2:57).

Saad Usmani highlights the phase 3 CANDOR trial findings demonstrating the survival benefits of adding daratumumab to carfilzomib and dexamethasone in the treatment of relapsed or refractory multiple myeloma (4:18).

Patrick Brown shares his phase 3 trial findings pitting blinatumomab against chemotherapy as post-reinduction therapy prior to allogeneic hematopoietic stem cell transplant in children and young patients with B-cell acute lymphoblastic leukaemia (4:04).  

Brian Hill discusses the phase 2 ZUMA-2 trial looking at the response to KTE-X19 in patients with relapsed or refractory mantle cell lymphoma (3:42).

Stephen Schuster gives the latest findings on mosunetuzumab showing durable response in poor prognosis patients with non-Hodgkin lymphoma (5:11). 

Ching-Hon Pui discusses phase 3 findings showing improved survival with dasatinib versus imatinib given alongside intensive chemotherapy for the treatment of children with Philadelphia chromosome-positive acute lymphoblastic leukaemia (3:47).

Jeff Sharman reports findings highlighting improved survival outcomes for treatment-naïve patients with chronic lymphocytic leukaemia taking acalabrutinib versus chlorambucil alongside obinutuzumab (4:13).

Vijaya Bhatt takes us through his research combining geriatric assessment with genetic profiling to better select precision treatment for individuals with acute myeloid leukaemia (6:48).

Yue Lynn Wang gives an overview of her team’s chronic lymphocytic leukaemia proliferation model, which has demonstrated the benefits of combining ibrutinib and venetoclax (5:11).

Seth Karol talks to us about his study of the B-cell lymphoma 2 inhibitor venetoclax showing a good response when combined with cytarabine in children and young adults with relapsed or refractory acute myeloid leukaemia (3:15).

Christoph Röllig reports findings suggesting that waiting for genetic and laboratory test results in order to get the right treatment may be a reasonable approach for clinically stable patients with acute myeloid leukaemia (7:47).

Deepu Madduri discusses her trial findings showing a good response to the CAR T-cell therapy JNJ-4528 in multiple myeloma patients with relapsed or refractory disease (2:53).

Ghassan Abou-Alfa takes us through the ClarIDHy results, which suggest that ivosidenib could be an option for IDH1-mutated, advanced cholangiocarcinoma (3:37).

Enrique Grande presents the IMvigor130 trial assessing front-line atezolizumab, either as monotherapy or alongside chemotherapy, in treatment-naïve individuals with locally advanced or metastatic urothelial carcinoma (5:54).

Peter Schmid discusses data pointing to a role for pembrolizumab in the neoadjuvant and adjuvant treatment of newly diagnosed, early-stage triple-negative breast cancer (3:32).

Dennis Slamon outlines the MONALEESA-3 findings showing that postmenopausal women with HR-positive, HER2-negative advanced breast cancer derive a survival advantage from combining the CDK4/6 inhibitor ribociclib with fulvestrant (1:47).

George Sledge Jr reports overall survival data for the MONARCH 2 trial investigating the addition of the CDK4/6 inhibitor abemaciclib to fulvestrant in women with HR-positive, HER2-negative metastatic breast cancer (2:49).

Adding a PARP inhibitor to maintenance bevacizumab therapy improves progression-free survival for advanced ovarian cancer regardless of BRCA mutation status (1:41).

Rowan Chlebowski discusses the latest update from the Women’s Health Initiative Dietary Modification clinical trial showing the positive impact of a healthy diet on the risk of breast cancer death in postmenopausal women. He also touches upon how the metabolic syndrome may modify this risk (5:52).

Ian Davis takes us through the potentially practice-changing results of the phase III ENZAMET trial evaluating the addition of enzalutamide to standard of care in men with castration-sensitive prostate cancer (3:04).

Hedy Kindler presents the phase III POLO trial of maintenance therapy with the PARP inhibitor olaparib in metastatic pancreatic cancer patients harbouring germline mutations in BRCA1 or BRCA2 (3:47).

Peter Hall reports on the GO2 trial that aimed to optimise chemotherapy with oxaliplatin and capecitabine in elderly and frail individuals with advanced gastro-oesophageal cancer (1:40).

Sara Hurvitz summarises the findings of the phase III MONALEESA-7 trial investigating the addition of ribociclib to endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer (3:21).

Anders Bjartell outlines the main results of the placebo-controlled TITAN trial of apalutamide in men with castration-sensitive prostate cancer receiving androgen deprivation therapy (2:19).

Presenting author Leisha Emens outlines exploratory efficacy analysis results from IMpassion130 showing that programmed cell death ligand 1 in immune cells is a robust predictive biomarker for selecting women with metastatic triple-negative breast cancer who may benefit from first-line atezolizumab plus nab-paclitaxel treatment (6:19).

Francois-Clement Bidard reports findings that circulating tumour cell count could help oncologists choose between first line hormone therapy and chemotherapy in women with oestrogen receptor positive, HER2-negative metastatic breast cancer (3:23).

Aditya Bardia explains the importance of research done by him and his colleagues validating pCR as a robust surrogate biomarker for outcomes particularly in women with triple negative and HER2-positive breast cancer (5:26).  

Ann Partridge discusses the E5103 study findings regarding the quality of life issues faced by women undergoing mastectomy and the need to continue monitoring them long term (5:14).

Presenting author Zaida Morante discusses findings showing that the greater the delay in initiating adjuvant chemotherapy the worse a woman’s outcome in terms of overall and disease-free survival (2:59).

Andrea DeCensi outlines his study findings demonstrating that low-dose tamoxifen 5 mg/day significantly lowers the recurrence of intraepithelial neoplasia versus placebo without increasing endometrial cancer and deep vein thrombosis (3:32).

Emiel Rutgers gives an overview of the 10-year follow-up results from the EORTC AMAROS trial demonstrating that radiotherapy has equivalent locoregional control to that of axillary lymph node dissection  but with a reduced risk of lymphedema (4:28).

Charles Geyer reports his phase III study findings showing the potential for adjuvant trastuzumab emtansine as a new standard of care in women with HER-2 positive, early breast cancer and residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy (7:56).

Frank Vicini discusses his research showing that while partial breast irradiation after lumpectomy is not equivalent to whole breast irradiation for long-term control of ipsilateral breast tumour recurrence, the difference is small (2:27). 

Jorge Cortes outlines the findings from the Quantum-R trial of quizartinib in patients with relapsed/refractory acute myeloid leukaemia with a FLT3-internal tandem duplication and a poor prognosis (5:58).

Frederick Locke discusses long-term follow-up results from the ZUMA-1 trial, demonstrating high rates of durable response to axicabtagene ciloleucel treatment among patients with refractory large B-cell lymphoma (4:28).

Study author Alok Khorana discusses the results of the CASSINI trial, demonstrating a reduction in venous thromboembolism during treatment with rivaroxaban among patients with cancer (2:54).

Piers Blombery comments on his study results demonstrating that the BCL2 Gly101Val mutation impairs binding of venetoclax to BCL2, leading to an increased risk of chronic lymphocytic leukaemia progression during treatment (2:56).

Richard Maziarz takes us through the long-term follow-up results of the JULIET trial indicating that the CAR T-cell therapy tisagenlecleucel has achieved a high response rate and enduring responses in adults with relapsed or refractory diffuse large B-cell lymphoma (6:38).

Viola Poeschel outlines findings from the FLYER trial, showing that a six-cycle R-CHOP plus rituximab regimen can be reduced to four cycles of R-CHOP plus rituximab without compromising efficacy in younger patients with diffuse large B-cell lymphoma and a favourable prognosis (4:33).

Presenting author Fausto Castagnetti discusses the results of their study assessing the best score to predict outcomes in older patients with chronic myeloid leukaemia (4:17).

Barbara Burtness talks through the results of the KEYNOTE-048 trial comparing pembrolizumab alone or with chemotherapy versus the EXTREME regimen for patients with recurrent or metastatic head and neck cancer (5:10).

Massimo Cristofanilli discusses the latest results from the PALOMA-3 trial investigating the addition of the CDK4/6 inhibitor palbociclib to fulvestrant in previously treated advanced breast cancer (5:21).

Hisham Mehanna describes the results of the De-ESCALaTE HPV  trial comparing cetuximab versus cisplatin for the treatment of low-risk oropharyngeal cancer patients undergoing radiotherapy (5:43).

Peter Schmid discusses the progression-free and interim overall survival results for atezolizumab plus nab-paclitaxel in the setting of metastatic triple-negative breast cancer (5:24).

Apostolia Tsimberidou discusses the findings of the IMPACT study, looking at the survival benefits of matching targeted treatments to the genetic alterations of tumors across multiple cancer types (7:56).

Arnaud Méjean presents the CARMENA trial findings, suggesting that cytoreductive nephrectomy may no longer be the standard of care for metastatic renal cell carcinoma in the era of sunitinib (4:21).

Joseph Sparano gives an overview of his team's findings regarding a 21-gene prognostic test that could help tailor treatment for women with early breast cancer (3:24).

Lead author Daniel George discusses his findings of a greater and longer lasting treatment effect with abiraterone acetate and prednisone in Black than White men with metastatic castration-resistance prostate cancer (3:59).